 Nicole Marjon
Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, G-Protein-Coupled | 3 | 2014 | 192 | 0.550 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2014 | 28 | 0.470 |
Why?
| | Carcinogenesis | 1 | 2014 | 180 | 0.420 |
Why?
| | Receptors, Formyl Peptide | 2 | 2016 | 9 | 0.220 |
Why?
| | Arrestins | 2 | 2016 | 14 | 0.210 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2199 | 0.190 |
Why?
| | Frozen Sections | 1 | 2019 | 24 | 0.160 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2019 | 100 | 0.150 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 280 | 0.150 |
Why?
| | Endometrial Neoplasms | 1 | 2018 | 141 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2016 | 88 | 0.120 |
Why?
| | CTLA-4 Antigen | 1 | 2015 | 77 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 67 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 139 | 0.120 |
Why?
| | Ovariectomy | 1 | 2014 | 116 | 0.110 |
Why?
| | Receptors, Estrogen | 2 | 2014 | 372 | 0.110 |
Why?
| | Hyperplasia | 1 | 2014 | 163 | 0.110 |
Why?
| | Tamoxifen | 1 | 2014 | 192 | 0.110 |
Why?
| | Estrogen Receptor alpha | 1 | 2014 | 121 | 0.110 |
Why?
| | Estrogens | 1 | 2014 | 312 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 388 | 0.090 |
Why?
| | Adaptor Protein Complex 2 | 1 | 2009 | 5 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2014 | 1951 | 0.080 |
Why?
| | Growth | 1 | 2009 | 56 | 0.080 |
Why?
| | Growth Disorders | 1 | 2009 | 77 | 0.080 |
Why?
| | Malnutrition | 1 | 2009 | 63 | 0.080 |
Why?
| | Body Height | 1 | 2009 | 180 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2014 | 2196 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2321 | 0.070 |
Why?
| | Prognosis | 1 | 2014 | 3334 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2009 | 342 | 0.060 |
Why?
| | Apoptosis | 2 | 2016 | 2369 | 0.060 |
Why?
| | Body Weight | 1 | 2009 | 869 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1895 | 0.060 |
Why?
| | Blood Pressure | 1 | 2009 | 1530 | 0.050 |
Why?
| | Protein Transport | 2 | 2016 | 396 | 0.050 |
Why?
| | Animals | 4 | 2016 | 31761 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2019 | 50 | 0.040 |
Why?
| | Pelvic Exenteration | 1 | 2018 | 11 | 0.040 |
Why?
| | Salpingo-oophorectomy | 1 | 2018 | 11 | 0.040 |
Why?
| | Hysterectomy | 1 | 2018 | 106 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2018 | 141 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 333 | 0.040 |
Why?
| | Protein Binding | 2 | 2016 | 1896 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2018 | 623 | 0.030 |
Why?
| | Medical Oncology | 1 | 2018 | 229 | 0.030 |
Why?
| | Obesity | 1 | 2009 | 2513 | 0.030 |
Why?
| | Gynecology | 1 | 2018 | 163 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1176 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 232 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 195 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 316 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2015 | 165 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2018 | 490 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 4406 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 928 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 854 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2015 | 313 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 384 | 0.030 |
Why?
| | Palliative Care | 1 | 2018 | 641 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2015 | 1122 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2015 | 722 | 0.020 |
Why?
| | Cell Movement | 1 | 2016 | 867 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1571 | 0.020 |
Why?
| | Immunotherapy | 1 | 2015 | 475 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 1846 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2582 | 0.020 |
Why?
| | U937 Cells | 1 | 2009 | 22 | 0.020 |
Why?
| | Nigeria | 1 | 2009 | 14 | 0.020 |
Why?
| | Mammary Arteries | 1 | 2009 | 6 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2009 | 152 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1270 | 0.020 |
Why?
| | World Health Organization | 1 | 2009 | 103 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2557 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 271 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 3890 | 0.020 |
Why?
| | Humans | 6 | 2019 | 114709 | 0.020 |
Why?
| | Endosomes | 1 | 2009 | 124 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6346 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 373 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 741 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 398 | 0.020 |
Why?
| | Female | 4 | 2018 | 59483 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 870 | 0.020 |
Why?
| | Mice | 2 | 2016 | 14916 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1151 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 4710 | 0.020 |
Why?
| | Vasodilation | 1 | 2009 | 415 | 0.020 |
Why?
| | Estradiol | 1 | 2009 | 455 | 0.020 |
Why?
| | Breast Feeding | 1 | 2009 | 370 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 8625 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1078 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9089 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 2209 | 0.010 |
Why?
| | Adult | 2 | 2018 | 30542 | 0.010 |
Why?
| | Signal Transduction | 1 | 2016 | 4521 | 0.010 |
Why?
| | Prevalence | 1 | 2009 | 2249 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 12511 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 1958 | 0.010 |
Why?
| | Rats | 1 | 2009 | 4943 | 0.010 |
Why?
| | Aged | 1 | 2018 | 19078 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 26747 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 5034 | 0.010 |
Why?
| | Infant | 1 | 2009 | 7932 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 9077 | 0.010 |
Why?
| | Male | 2 | 2009 | 55554 | 0.010 |
Why?
|
|
Marjon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|